The Diversity of the Fungal and Bacterial in Colon Mucosa of Patients With Different Degree of Inflammation of Ulcerative Colitis

Overview

We analyzed the diversity of the fungal and bacterial within colon mucosa between patients with different degree of inflammation of Ulcerative Colitis.

Full Title of Study: “The Diversity of the Fungal and Bacterial in Colon Mucosa of Patients With Ulcerative Colitis Associated Different Clinical Classification”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2017

Detailed Description

In recent years, the relationship of intestinal fungus with inflammatory bowel disease was gradually revealed. We divided the patients with ulcerative colitis into three groups on the basis of World Gastroenterology Organisation (WGO) classification about inflammation degree and progress classification and established the healthy control group. Analyzing the diversity of the fungal and bacterial within colon mucosa between patients with different clinical classification, for example, the proportion of bacteria and fungi, the proportion of candida albicans, the proportion of yeasts, and so on.

Interventions

  • Other: ulcerative colitis
    • We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
  • Other: Control
    • We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.

Arms, Groups and Cohorts

  • ulcerative colitis
    • We analysed the diversity of the fungal and bacterial in patients with Ulcerative Colitis (UC). We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
  • Control
    • Analysing the diversity of the fungal and bacterial in patients without ulcerative colitis. We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.

Clinical Trial Outcome Measures

Primary Measures

  • fungus detection rate
    • Time Frame: 6 months
    • Fungi detection rate was defined as the percentage of patients in whose colonic mucosa at least one kind of fungus were identified.
  • yeasts detection rate
    • Time Frame: 6 months
    • Yeasts detection rate was defined as the percentage of patients in whose colonic mucosa yeasts were identified.
  • candida albicans detection rate
    • Time Frame: 6 months
    • Candida albicans detection rate was defined as the percentage of patients in whose colonic mucosa candida albicans were identified.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients at our tertiary care medical center, aged between 18 and 80 years, scheduled to undergo surveillance colonoscopy. – The patients with ulcerative colitis for ulcerative colitis group. – The patients without ulcerative colitis for control group. – 18-80 years. Exclusion Criteria:

  • Using antibiotics, glucocorticoid and immunosuppressants wintin one month. – There are contraindications for enteroscopy and biopsy. – There are other intestinal diseases. – Pregnancy or breast-feeding women. – Patients with serious lung disease and mental illness.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Xiuli Zuo
  • Collaborator
    • Qilu Hospital of Shandong University
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Xiuli Zuo, Deputy director of the physician – Shandong University
  • Overall Official(s)
    • Xiuli Zuo, PhD, Principal Investigator, Qilu Hospital of Shandong University
  • Overall Contact(s)
    • Xiuli Zuo, PhD, 15588818685, zuoxiuli@sina.com

Citations Reporting on Results

Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, Cohen D, Liguori G, Bourrier A, Nion-Larmurier I, Cosnes J, Seksik P, Langella P, Skurnik D, Richard ML, Beaugerie L. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun;66(6):1039-1048. doi: 10.1136/gutjnl-2015-310746. Epub 2016 Feb 3.

Mukhopadhya I, Hansen R, Meharg C, Thomson JM, Russell RK, Berry SH, El-Omar EM, Hold GL. The fungal microbiota of de-novo paediatric inflammatory bowel disease. Microbes Infect. 2015 Apr;17(4):304-10. doi: 10.1016/j.micinf.2014.12.001. Epub 2014 Dec 15.

Eriksson M, Johannssen T, von Smolinski D, Gruber AD, Seeberger PH, Lepenies B. The C-Type Lectin Receptor SIGNR3 Binds to Fungi Present in Commensal Microbiota and Influences Immune Regulation in Experimental Colitis. Front Immunol. 2013 Jul 16;4:196. doi: 10.3389/fimmu.2013.00196. eCollection 2013.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.